Rates of uninsured dropped faster than almost anywhere in the nation, but Kynect is part of "Obamacare," and the new Republican Governor Matt Bevin has vowed that it must go. Advocates have a lot of questions about how hard-to-target populations will be reached and whether grant funds will have to be repaid.
The kit began with a petition from an 11-year-old girl with T1D who wanted a doll that looked "just like me."
The state's new secretary of Health and Hospitals said she will need to hire 248 workers to replace those let go under former Governor Bobby Jindal if her agency is to enroll all those expected to pursue coverage under expansion.
The principal investigator at Seattle Children's said prior work has shown that intensive interventions can be effective in fighting obesity, but they are rarely covered by insurance.
The latest developments across the healthcare landscape and key upcoming conferences to attend.
Researchers examine the policy of taxing unhealthy foods and drinks in order to reduce rates of obesity, diabetes, hypertension, and other conditions linked to poor eating habits.
A recent safety trial has found a promising new therapy for type 1 diabetes that uses patients’ own regulatory T-cells instead of the usual immunosuppressive drugs to protect beta cells.
Top managed care stories include Sanofi ending its deal to market Afrezza, Aetna cut ties with America's Health Insurance Plans, and a new study found bankruptcy looms large for cancer survivors.
The guidelines show the influence of lobbyists, raising questions about how they will be created in future cycles. They will next be updated in 2020.
Analyzing factors associated with continuing care participation in patients with diabetes and with interrupted participation by patients enrolled in a diabetes pay-for-performance program.
The findings on salt intake were timed to coincide with the release of the 2015 Dietary Guidelines for Americans.
Last February, the Dietary Guidelines Advisory Committee trumpeted its recommendations to promote sustainability and curtail consumption of red and processed meat. After a year of intense lobbying, neither item made survived the final cut in the 2015 report released today.
Disappointing sales were blamed on prior authorization, the FDA label restrictions, and the need for spirometry before doctors could write prescriptions.
The trials would involve the University of Virginia School of Medicine and Harvard's Paulson School of Engineering and Applied Science
Study finds kids in an urban district picked healthy food after changes to the school lunch program, but it doesn't measure whether they ate it.
The research has important implications for finding a potential cure for type 1 diabetes.
Studies that provided updates on new drug trials, sessions on value-based care, and the cost of healthcare, were most popular among readers of The American Journal of Managed Care.
Bariatric surgery is becoming a more popular method to address obesity, so physicians and surgeons should be more aware of how time of year affects outcomes.
Stories about therapy, led by updates on Afrezza, were most popular with readers interested in diabetes care.
The prior CEO of MannKind attributed slow sales of Afrezza in part to slow reimbursement from insurers.
A new study has provided the first strong evidence that warfarin can interact adversely with anti-diabetes drugs and cause serious hypoglycemic events.
It appears Sanofi will use a priority review voucher to catch up in the process to Novo Nordisk, which submitted an NDA for Xultophy in late September.
The effort aims to prevent diabetes by urging Americans to get annual checkups and know 4 key numbers: BMI, blood pressure, blood sugar, and cholesterol.
The award is believed to be the largest in Indiana under the Americans with Disabilities Act for a person with diabetes.
Sessions on obesity and the role of technology in disease management will be part of the annual gathering of stakeholders, presented by The American Journal of Managed Care, April 7-8, 2016, at the Teaneck Marriott at Glenpointe in Teaneck, New Jersey.